I also think that the partnership with Cencora is a good idea although it would be nice to know a few more details such as the general financial arrangement of the deal. I think a very key differences between this deal and RVX's deal with Eversana are the much larger size and likely market access of Cencora as compared to Eversana and also the fact that Zenith has numerous active and promising trials as compared to RVX which is seemingly dead in the water and without any meaningful leadership.